Utah Medical Products Increases Quarterly Cash Dividend by 1.6% to $0.31 per Share
Board Appointment: Utah Medical Products has appointed Kevin C. Timken, Esq to its board of directors.
Dividend Announcement: The board approved a quarterly cash dividend of 31 cents per share of common stock.
Payment Date: The dividend is payable on January 5 to shareholders of record as of December 16.
Dividend Increase: This dividend represents a 1.6% increase over the previous regular quarterly cash dividend.
Trade with 70% Backtested Accuracy
Analyst Views on UTMD
About UTMD
About the author
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
Daily Dividend Report: WELL,PFG,CTVA,UTMD,ENB,WFC
Dividend Increases Announced: Several companies, including Principal Financial Group, Corteva, Utah Medical Products, Enbridge, and Wells Fargo, have announced increases in their quarterly dividends for 2025, reflecting a commitment to returning capital to shareholders.
Upcoming Dividend Payment Dates: The declared dividends will be payable on various dates in September and October 2025, with specific record dates for shareholders noted for each company.
Top Analyst Reports for JPMorgan, Novartis & AT&T
Research Reports on Major Stocks: The Zacks Research Daily highlights new reports on 16 significant stocks, including JPMorgan Chase, Novartis, and AT&T, along with insights into micro-cap companies like Perma-Pipe International and Utah Medical Products, emphasizing unique research on smaller firms.
Market Trends and Company Performance: Key findings indicate that JPMorgan is expected to see net interest income growth despite fee income challenges, Novartis benefits from a strong drug portfolio amid competition, and AT&T continues to thrive in the wireless sector while facing challenges in its wireline division.
Validea Benjamin Graham Strategy Daily Upgrade Report - 6/18/2025
Validea's Value Investor Model: The model, based on Benjamin Graham's strategy, has upgraded Utah Medical Products Inc (UTMD) from a 71% to an 86% rating due to improved fundamentals and valuation, indicating strong interest in the stock.
Company Overview: Utah Medical Products, Inc. specializes in developing medical devices for women's healthcare and critical care, offering a variety of products including those for postpartum hemorrhage control and neonatal care.
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
Daily Dividend Report: WELL,PFG,CTVA,UTMD,ENB,WFC
Dividend Increases Announced: Several companies, including Principal Financial Group, Corteva, Utah Medical Products, Enbridge, and Wells Fargo, have announced increases in their quarterly dividends for 2025, reflecting a commitment to returning capital to shareholders.
Upcoming Dividend Payment Dates: The declared dividends will be payable on various dates in September and October 2025, with specific record dates for shareholders noted for each company.
Top Analyst Reports for JPMorgan, Novartis & AT&T
Research Reports on Major Stocks: The Zacks Research Daily highlights new reports on 16 significant stocks, including JPMorgan Chase, Novartis, and AT&T, along with insights into micro-cap companies like Perma-Pipe International and Utah Medical Products, emphasizing unique research on smaller firms.
Market Trends and Company Performance: Key findings indicate that JPMorgan is expected to see net interest income growth despite fee income challenges, Novartis benefits from a strong drug portfolio amid competition, and AT&T continues to thrive in the wireless sector while facing challenges in its wireline division.
Validea Benjamin Graham Strategy Daily Upgrade Report - 6/18/2025
Validea's Value Investor Model: The model, based on Benjamin Graham's strategy, has upgraded Utah Medical Products Inc (UTMD) from a 71% to an 86% rating due to improved fundamentals and valuation, indicating strong interest in the stock.
Company Overview: Utah Medical Products, Inc. specializes in developing medical devices for women's healthcare and critical care, offering a variety of products including those for postpartum hemorrhage control and neonatal care.
